Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Targeted treating medicine for cardiac microangiopathy caused by Coxsackie B3 virus infection

A microvascular disease, targeted therapy technology, applied in the field of biomedicine, can solve the problems of functional impairment, cardiac microvascular endothelial cell apoptosis, etc., and achieve the effect of alleviating myocardial tissue lesions

Inactive Publication Date: 2019-03-22
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previous studies have demonstrated that coxsackievirus B3 (CVB3) infection leads to apoptosis of cardiac microvascular endothelial cells (CMVECs), resulting in impaired function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeted treating medicine for cardiac microangiopathy caused by Coxsackie B3 virus infection
  • Targeted treating medicine for cardiac microangiopathy caused by Coxsackie B3 virus infection
  • Targeted treating medicine for cardiac microangiopathy caused by Coxsackie B3 virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0041] The miRNA21antagomir inhibitor can protect the cardiac microvessels of viral myocarditis model mice by inhibiting the high expression of miRNA21, and improve the effect of myocarditis myocardial tissue lesions.

[0042] 1. Establishment of viral myocarditis mouse model

[0043] 1. Virus passage and titration

[0044] Coxsackie B3 virus (CVB3) (Nancy strain, kept in our laboratory) was subcultured and replicated on Vero cells. After the virus was harvested, the virus virulence was measured on Hela cells, and TCID50 was calculated by Reed method.

[0045] 2. Experimental animals and grouping

[0046] Fifty-six Balb / C clean-grade mice, 4-5 weeks old, male, weighing 12-15g, were provided by Shanghai Slack Experimental Animal Co., Ltd. Mice were randomly divided into virus control group (n=10), normal control group (n=6), miRNA21agomir group (n=10), miRNA21agomir negative control group (n=10), miRNA21antagomir group (n=10), miRNA21agomir group (n=10), Negative control gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biomedicines, and particularly discloses a targeted treating medicine for cardiac microangiopathy caused by Coxsackie B3 virus infection. The targeted treating medicine is miRNA21antagomir, and the nucleotide sequence is 5'-UCAACAUCAGUCUGAUAAGCUA-3'. The targeted treating medicine is an inhibitor specifically targeting highly-expressed miRNA21 in cardiac microvascular endothelial cells, specifically targets highly-expressed miRNA21 molecules, weakens the gene silencing effect of endogenous miRNA21, and inhibits apoptosis of the vascular endothelial cells to maintain the normal physiological functions of microvessels by increasing the expression quantity of target gene protein and regulating related signaling pathways. The targeted treating medicine can be used for treating the cardiac microangiopathy caused by the Coxsackie B3 virus infection, blocks migration of pathogenic factors to a target organ, alleviates myocardial tissue lesions,and is a novel treating medicine for viral myocarditis intervention.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a targeted therapeutic drug for cardiac microangiopathies caused by Coxsackie B3 virus infection. Background technique [0002] The importance of vascular endothelial cells to the structural integrity of blood vessels and to maintain their normal physiological functions has been increasingly recognized. Studies have found that cardiac microvascular disease is the initial process and common pathway of many cardiovascular diseases such as viral myocarditis and dilated cardiomyopathy (VMC&DCM). Risk factors such as viral infection initiate or aggravate the pathological process of these diseases through damage to endothelial cells and run through them. Therefore, early diagnosis and active intervention in the treatment of cardiac microvascular lesions, timely blocking the path of pathogenic factors migrating to target organs, are of great significance for the prevention or treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7105A61K48/00A61P31/14A61P9/00
CPCA61K31/7105A61P9/00A61P31/14
Inventor 陈瑞珍虞勇李明辉虞莹邹云增葛均波
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com